Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Publication | Closed Access

DOI

Citations

References

2020

Year

Patrick Schöffski, Olivier Mir, Bernd Kasper, Zsuzsanna Pápai, Jean‐Yves Blay, Antoîne Italiano, Charlotte Benson, Kateřina Kopečková, Nasim Ali, Palma Dileo,

European Journal of Cancer

European OrganisationGastrointestinal Oncology‘ Cabogist ’MedicinePharmacologyPharmacotherapyMolecular OncologyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer Research